• 1.Key Characteristics

• 2. R&D Strategy

• 3. Pipeline Outlook

• 4. Biotechnology

Biologicals as VEGF and VEGF-R antagonists

• 1. Biologicals as VEGF and VEGF-R antagonists

• 2005 sales of 2.425 bln € with 22.3 % profitability;
• single biggest selling product: Puregon (rFSH) with 355 mln €;
• key growth drivers: Nuvaring, Puregon and Esmeron;
• in preparation of IPO

• Short term leverage of traditional positions in gynecology, fertility and anesthesia;
• Mid-term rebuilding of neuroscience franchise;
• Long-term etablishment of biotechnology as platform of future growth

• Six products for filing in next 4-5 years;
• Eight projects in phase II;
• Seven projects in phase I;
• 17 projects in preclinical development

• Biotech center in Cambridge , MA ;
• Focus on immunology and oncology;
• Currently ten antibody-based projects ongoing;
• Expanding biologics pipeline by partnerships and acquisitions

• Use of VEGF and VEGF-R antagonists in ophthalmology and oncology;
• Biological classes include antibodies, proteins, peptides, DNA and RNA molecules;
• Class-leading products are Macugen in wet AMD and Avastin in cancer;
• ImClone with broad antibody-based approach for VEGF-R antagonists